Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.

Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.

Target Oncol. 2013 Feb 21;

Authors: Sikaria S, Heim-Hall J, Diaz EH, Williams R, Sankhala K, Laabs B, Mita M

PMID: 23430345 [PubMed - as supplied by publisher]

zm-447439 rad001 ecdysone